文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

金属伪影减少用于3T MRI-only前列腺放疗合并髋关节假体患者:靶区定义、合成CT生成、剂量计算与基准标记识别的影响

Metal artifact reduction for 3 T MRI-only prostate radiotherapy in patients with hip prostheses: impact on target definition, synthetic CT generation, dose calculation, and fiducial marker identification.
PubMed 文献 · Radiat Oncol · 2026-09-07

该概念验证研究纳入5例合并髋关节假体并置入前列腺内基准标记的前列腺癌患者,评估仅使用MAVRIC-SL序列完成3T MRI-only放疗流程的可行性。结果显示靶区勾画、标记识别与合成CT生成均成功,基于假体信号缺损定义的照射野规避扇区计划与常规CT定义扇区的剂量学差异在PTV中位≤0.1%、危及器官-0.4%至+0.7%,合成CT计划在CT上重算的γ通过率中位为99.1%(2%/2 mm)和96.4%(1%/1 mm)。

要点

  • 仅用MAVRIC-SL即可完成勾画、合成CT生成与基准标记识别。
  • 基于假体信号缺损定义的规避扇区计划剂量学与CT定义者接近。
  • 合成CT计划在CT上重算的γ通过率中位达99.1%(2%/2 mm)。

核心结论

  • 合并髋关节假体的前列腺癌患者可采用仅MAVRIC-SL的3T MRI-only放疗流程,完成勾画、合成CT生成、剂量计算与基准标记识别。

研究设计与样本

  • 概念验证研究,纳入5例合并单侧或双侧髋关节假体并置入前列腺内基准标记的前列腺癌患者,回顾性使用CT、标准3T MRI及额外MAVRIC-SL MRI,不改变患者治疗。
  • 每例基于常规CT定义的规避扇区AS1与基于MAVRIC-SL假体信号缺损定义的规避扇区AS2各制定一个42.7 Gy/7次计划,并行剂量体积直方图参数比较。

主要发现

  • MAVRIC-SL成功完成靶区勾画、基准标记识别与合成CT生成。
  • AS1与AS2计划的中位剂量差异在PTV为±0.1%以内,危及器官指标范围为-0.4%至+0.7%。
  • AS2计划在配准CT上重算后,PTV剂量差异≤0.9%,危及器官≤1%。
  • 中位γ通过率为99.1%(2%/2 mm)与96.4%(1%/1 mm,10%剂量阈值)。

关键数值与推荐

  • 处方剂量42.7 Gy,7次。
  • PTV中位剂量差异:AS1与AS2计划间±0.1%以内;AS2计划在CT重算后≤0.9%。
  • 危及器官剂量差异:AS1与AS2计划间-0.4%至+0.7%;AS2计划在CT重算后≤1%。
  • γ分析通过率中位:99.1%(2%/2 mm)与96.4%(1%/1 mm,10%剂量阈值)。

临床怎么用

  • 对合并髋关节假体的前列腺癌患者,可尝试仅用MAVRIC-SL序列完成MRI-only放疗流程,避免CT-MRI配准不确定性。
  • 基准标记在MAVRIC-SL中不可见时,可将原始数据重建为光谱 bin 图像手动识别标记。
  • 利用MAVRIC-SL中假体信号缺损定义照射野规避扇区,以减少射线穿过植入物带来的剂量计算与投照不确定性。

局限性

  • 研究为5例患者的概念验证,样本量小。
  • 所有图像回顾性使用,未影响患者治疗。
  • 基准标记在MAVRIC-SL中不可见,需依赖原始数据重建的光谱 bin 图像手动识别。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Magnetic resonance imaging (MRI) offers superior soft-tissue contrast and MRI-only radiotherapy (RT) eliminates uncertainties associated with computed tomography (CT)-to-MRI image registration. An MRI-only RT workflow in patients with hip prostheses remains challenging since delineation, synthetic CT (sCT) generation, and marker identification ideally rely on MR images, which are sensitive to distortions. Metal-artifact reduction sequences (MARS) mitigate metal distortions but often obscure gold markers. The aim of this study is to present a proof-of-concept 3 T MRI-only RT workflow for prostate cancer patients with hip prostheses, using only MARS MAVRIC-SL (GE HealthCare) for delineation, sCT generation and fiducial marker identification. METHODS: Five prostate cancer patients with one or two hip prostheses and intraprostatic fiducial markers underwent CT, standard 3 T MRI and additional MAVRIC-SL MRI. All images were used retrospectively and did not affect patient treatment. Delineation and sCT generation were performed using MAVRIC-SL. Intraprostatic markers were not visible in MAVRIC-SL due to artifact suppression; instead, raw data were reconstructed into spectral-bin images to manually identify the markers. To prevent incoming radiation from passing through the implants and reduce the associated uncertainties in dose calculation and treatment delivery, beam avoidance sectors (AS) were applied. Conventional CT-based avoidance sectors were registered to the sCT and defined as AS1. Prosthesis-induced signal voids in MAVRIC-SL were used to define AS2. Two treatment plans (42.7 Gy, 7 fractions) were created per patient using AS1 and AS2. Plans were compared using dose-volume histogram (DVH) parameters. AS2-plans were recalculated on registered CTs for DVH-comparison and gamma analyses (2%/2 mm and 1%/1 mm with 10% dose threshold) were performed. RESULTS: Delineation, marker identification and sCT generation were successful using MAVRIC-SL. Median dose differences between AS1 and AS2 remained within ± 0.1% for PTV, while OAR metrics ranged from - 0.4% to + 0.7%. AS2-plans recalculated on CT showed dose differences ≤ 0.9% for PTV and ≤ 1% for OARs. Median gamma pass rates were 99.1% (2%/2 mm) and 96.4% (1%/1 mm). CONCLUSIONS: This study demonstrates the feasibility of an MRI-only radiotherapy workflow at 3 T for prostate cancer patients with hip prostheses, enabling delineation, sCT generation, dose calculation and marker identification from a single MAVRIC-SL acquisition. CLINICAL TRIAL NUMBER: Not applicable.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Coskun M, Petersson JS, Wetterstedt SA, et al. Metal artifact reduction for 3 T MRI-only prostate radiotherapy in patients with hip prostheses: impact on target definition, synthetic CT generation, dose calculation, and fiducial marker identification. Radiat Oncol. 2026. PMID: 42711722. doi:10.1186/s13014-026-02922-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。